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Summary
Purpose. With improvements in breast imaging and image-guided interventions, there is interest in ablative tech-
niques for breast cancer. Cryosurgery initiates inflammation and leaves tumor-specific antigens intact, which may
induce an anti-tumor immune response. To help define the mechanisms involved in the cryoimmunologic response,
we compared cryosurgery to surgery in a murine model of breast cancer.
Experimental design. BALB/c mice with MT-901 tumors underwent cryoablation or resection. Mice successfully
treated were re-challenged with MT-901 or RENCA. Serum cytokine levels were analyzed by ELISA. Tumor
draining lymph nodes (TDLN) and spleens were harvested, lymphocytes were activated and assessed for a specific
anti-tumor response by both an interferon-c (IFNc) release assay and ELISPOT. NK cell activity was assessed by
cytotoxicity against YAC-1, an NK-susceptible cell line.
Results. After re-challenge, tumors developed in 86% of mice treated by surgical excision compared to 16% of
mice treated by cryosurgery (p ¼ 0.025). Cryoablation of MT-901 had no effect on re-challenge with RENCA.
Cryoablation led to significantly higher levels of interleukin (IL)-12 (383.6 pg/ml ± 32.8 versus 251.6 ± 16.5,
p ¼ 0.025) and IFN-c (1564 pg/ml ± 49 versus 1244 pg/ml ± 101, p ¼ 0.009), but no changes in IL-4 or IL-10.
Tumor-specific T-cell responses were evident after cryosurgery in lymphocytes from TDLN but not from spleen.
Cryoablation also increased NK activity compared to surgery (24.5% ± 17.3 versus 16.5% ± 5.9, p < 0.001).
Conclusion. Cryoablation results in the induction of both a tumor-specific T-cell response in the TDLN and
increased systemic NK cell activity, which correlates with rejection of tumors upon re-challenge.
Introduction
In 2004 there will be over 217,000 cases of female breast
cancer diagnosed in the United States, making it the most
common malignant tumor in women [1]. With no differ-
ence in survival between breast conservation therapy and
mastectomy, there has been a dramatic shift in surgical
therapy towards less radical and disfiguring treatments
[2]. Improvements in imaging have increased detection of
cancers under 1.0 cm [3], and the technology for image-
guided interventions has also improved, accelerating in-
tense interest in non-surgical ablative techniques for
treating breast cancer. Several methods for the in situ
ablation of breast cancer are presently being investigated,
including radiofrequency ablation (RFA), cryosurgery,
laser interstitial therapy, high intensity focused ultra-
sound, and focused microwave thermotherapy (FMT) [4,
5].
With the exception of cryosurgery, all the above
mentioned techniques use hyperthermia, causing melting
and fusing of cell membranes and protein denaturation.
In contrast, cryosurgery leaves tumor proteins and tu-
mor-associated antigens intact. The presence of residual
tumor antigens in an inflammatory microenvironment
can stimulate anti-tumor immune responses [6]. Cryo-
surgery has been successfully used for the ablation of
tumors in the liver [7, 8], prostate [9, 10], kidney tumors
[11, 12], the palliative treatment of locally advanced
breast cancers [13 14], and the treatment of breast fi-
broadenomas [15]. In several cases there were reports of
effects distant from the primary tumor, suggesting a
cryoimmunologic benefit to cryosurgery [13, 16–18]. If
the cryoablation of breast cancer can induce an anti-
tumor immune response capable of reducing both local
and distant recurrence, then this approach may not only
be superior to other ablative technologies, but perhaps
even to surgical excision. To examine this possibility and
define the mechanisms involved in the cryoimmunologic
response, we compared cryosurgery to surgery in a
murine model of breast cancer.
Materials and methods
Animals
Six- to 8-week-old female BALB/c mice were purchased
from The Jackson Laboratory (Bar Harbor, NE, USA)
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and maintained in specific pathogen-free conditions at
the Animal Maintenance Facility of the University of
Michigan Medical Center.
Tumors
MT-901 is a subline of a murine tumor cell line derived
from a dimethylbenzantracene-induced mammary carci-
noma in the BALB/c strain. This tumor is weakly
immunogenic and expresses MHC class I but not MHC
class II molecules. RENCA is an immunogenic murine
renal cell carcinoma of spontaneous origin in the BALB/c
strain. Line-1 is a BALB/c lung alveolar carcinoma cell
line. YAC-1 is an NK-susceptible murine lymphoma cell
line. Cell lines were maintained in complete media con-
sisting of RPMI 1640 supplemented with 10% heat-acti-
vated fetal bovine serum, 0.1 mM nonessential amino
acids, 1 lM sodium pyruvate, 100 lg/ml streptomycin,
100 units/ml penicillin, 50 lg/ml gentamycin and 0.5 lg/
ml fungizone, all from Life Technologies, Inc. (Grand
Island, NY, USA). Tumors were generated in vivo s.c.
injection of BALB/c mice with 3 · 105 viable MT-901
cells.
Surgical procedures
Mice were placed in sanitized laminar flow hoods and
anesthesized with xylazine & ketamine by intraperito-
neal injection, then placed in a prone position and the
tumor site prepared with alcohol. Procedures were per-
formed using strict aseptic technique. Wide excision
surgical resections were performed with grossly negative
surgical margins. After control of self-limited hemor-
rhage was obtained, the wound was closed with inter-
rupted nylon sutures.
A table-top Argon-gas-based cryoablation system
(Visica Cryoablation System, Sanarus Medical, Pleas-
anton, CA, USA), designed to create probe tempera-
tures of –160C was used to perform cryoablation.
Anesthesized mice were placed in a prone position on a
heating pad to avoid hypothermia and the tumor site
prepared with alcohol. The overlying skin was divided
and retracted away from the tumor using strict aseptic
technique. The freezing tip of the cryoprobe was placed
into the tumor mass under direct vision and a 30-s freeze
was accomplished by the flow of Argon gas through the
probe. The 30-s freeze was repeated if the entire mass
was incompletely frozen. The mass and probe were then
allowed to passively thaw and the probe was removed.
The skin was then closed over the ablated tumor using
interrupted Nylon sutures. All mice were placed under a
warming lamp during the recovery period.
Tumor-draining lymph node (TDLN) cells and splenocyte
activation
At varying time points after either cryoablation or sur-
gery, TDLN and splenocytes were removed aseptically.
Lymphoid cell suspensions were prepared by mechanical
dissociation with 25-gauge needles and pressed with the
blunt end of a 3-ml plastic syringe in RPMI 1640. Spleen
cells obtained from BALB/c mice were treated with
ammonium chloride–potassium lysis buffer (0.83%
ammonium chloride, 0.1% KHCO3 and 0.004% EDTA)
for 1 min to deplete erythrocytes and were washed twice
with HBSS. The cells were activated with 1 lg/ml anti-
CD3 monoclonal antibody (mAb) immobilized in 24-
well plates (4 · 106 cells/2 ml/well) for 2 days. The cells
were subsequently cultured in recombinant human in-
terlecukin (IL-2) (Chiron Therapeutics, Emeryville, CA,
USA) at 60 IU/ml IL 2 for 3 days at 2 · 105 cells/ml.
In vitro cytokine release assay
1 · 106 Activated TDLN or splenocytes were co-cul-
tured with 5 · 105 MT-901 tumor cells irradiated to
15,000 cGy in 2 ml of CM per well of a 24-well tissue
culture plate. IL-2 (4 IU/ml) was added at the beginning
of the cultures. The supernatents were collected and,
after centrifugation, analyzed for interferon-c (IFN-c)
using commercially available ELISA kits from PharM-
ingen. Standard curves were established per manufac-
turer’s instructions with serial two-fold dilutions.
Experimental values were computed with the use of
regression analysis.
Serum cytokine levels
One hundred micro litres of blood was obtained from
mice 1 day after treatment (either cryosurgery or sur-
gery) by a standard tail vein bleed. The specimens were
centrifuged and the serum was collected and analyzed
for IFN-c, interleukin (IL)-12 IL-4 and IL-10 using
commercially available ELISA kits from PharMingen.
A standard curve starting at 1000 U/ml was established
with 11 serial two-fold dilutions was performed.
Experimental values were computed with the use of
regression analysis.
ELISPOT assay
The number of IFN-c producing cells was measured
using ELISPOT assay at varying time points after either
cryoablation or surgical excision. Briefly, 96-well plates
were coated with antimouse IFN-c antibody (Pharmin-
gen). Activated splenocytes (2 · 105 cells/well) were
cultured for 48 h at 37 C in a 5% CO2 incubator alone
or in the presence of 5 · 105 irradiated MT-901 or
RENCA tumor cells. After that time, wells were washed
and incubated overnight at 4 C with a different clone of
biotinylated anti IFN-c antibody (PharMingen). Reac-
tions were visualized and counted using anti-biotin-AP.
Cytotoxicity assay
To examine NK cell function, we performed a cytotox-
icity assay against YAC-1, an NK-susceptible cell line
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[19]. Briefly, activated effectors were plated in 96 well
plates, in 10% FBS/DMEM complete media (supple-
mented with HEPES, Sodium pyruvate, non-essen-
tial amino acids, 2-ME, and Pen/Strep) at (1:1) serial
dilutions starting with 1 · 106 cells/well. YAC-1 targets
were labeled with 51Cr at 0.15mCi/6 · 106 cells/530 ll
for 90 min at 37C under an atmosphere of 7.5% CO2.
Targets were then washed three times with 40 ml media,
and plated at effector:target ratios beginning at 40:1.
Spontaneous and total 51Cr release were calculated from
media plus targets only, and targets plus 1% Triton-X-
100, respectively. Plates were centrifuged at 1000 rpm for
3 min, then cultured for 4 h at 37C under an atmo-
sphere of 7.5% CO2. At the end of the incubation period,
20 ll of supernatant was collected and applied to a Lu-
maplate, dried, and counts were read using a TopCount
NXT scintillation/luminescence microplate reader. The
% Specific Lysis was calculated using the formula {%
Specific Lysis ¼ 100% · (Lysis ) Average Spontane-
ous Lysis)/(Average Total Lysis ) Lysis)}. The percent-
ages of specific lysis were averaged for each data point
(E:T ratio) to obtain standard deviations and graphed
using Deltagraph software. The p values were deter-
mined using t-test assuming equal variances.
Results
Cryoablation results in increased protection against
re-challenge compared to surgical resection
In order to demonstrate whether mice that underwent
cryoablation of subcutaneous MT-901 tumors devel-
oped an anti-tumor immune response, successfully
treated mice underwent tumor re-challenge. BALB/c
mice were inoculated with 3 · 105 MT-901 cells in the
right flank. On day 11, all mice with palpable subcuta-
neous tumors underwent either cryoablation or surgical
resection of their tumors. Two weeks later, all tumor-
free mice (80%) were re-inoculated on the left flank with
an identical tumorigenic dose of MT-901 cells. To gauge
the tumor-specific nature of this response, mice treated
by cryosurgery were re-inoculated with RENCA cells.
By day 10 after re-inoculation, six of seven mice treated
by surgical excision had grown tumors in the left flank
whereas only one of six mice treated by cryosurgery
grew tumors (p ¼ 0.025). Four of five mice treated for
MT-901 tumors by cryoablation grew RENCA tumors,
suggesting this was a tumor-specific immune response
(Figure 1).
Cryoablation results in an increase of Th1-type cytokines
but not Th2-type cytokines compared to surgical excision
In order to evaluate the mechanisms contributing to this
response, blood draws were performed 24 h after either
cryoablation or surgical excision, and serum levels of Th1
(IL-12, IFN-c) and Th2 (IL-4, IL-10) cytokines were
measured using commercially available ELISA kits.
Groups of fivemicewere compared by unpaired Student’s
t-test. The results are summarized in Figure 2. Cryosur-
gerywas associatedwith significantly higher levels of both
IL-12 (383.6 pg/ml ± 32.8 versus 251.6 ± 16.5,
p ¼ 0.025) and IFN-c (1564 pg/ml ± 49 versus 1244 pg/
ml ± 101, p ¼ 0.009) compared to mice undergoing
surgical excision. Serum levels of IL-4 and IL-10 were not
significantly different.
Cryoablation induces tumor-specific pre-effector cells
regionally but not systemically
Mice with MT-901 tumors treated by either cryoablation
or surgical excision were sacrificed at varying time points,
and lymphocytes from both TDLN and spleens were
evaluated in vitro. Lymphocytes from mice treated by
cryoablation secreted dramatically higher release of IFN-
c in response to MT-901 tumor cells than to Line-1 cells
(an irrelevant tumor) after treatment (Figure 3). Mice
treated by surgical excision exhibited similar responses to
MT-901 and Line-1.
The tumor specific response observed in TDLN was
not seen in splenocytes. As shown in Figure 4, lym-
phocytes secreted equivalent amounts of IFN gamma in
both treatment groups. Similar responses were observed
to MT-901 or Line-1 cells whether mice had been treated
by cryosurgery or surgical excision. Similar results were
seen on day 19. To evaluate further the systemic T-cell
response, IFN-c producing cells that specifically recog-
nized MT-901 cells were counted by ELISPOT assay.
Cryoablation and surgical excision resulted in similar
responses to MT-901 cells (Figure 5).
Cryoablation leads to increased NK cell cytotoxicity
compared to surgical excision
Mice treated were killed 1 week after treatment, and the













































Figure 1. Tumor re-challenge after cryosurgery or surgical excision.
BALB/c mice underwent cryoablation or surgical excision of subcu-
taneous MT-901 tumors. Two weeks later they were re-challenged with
tumorigenic doses of either MT-901 or RENCA cells. By day 10 after
re-inoculation, six of seven mice treated by surgical excision had grown
tumors in the left flank. In mice treated by cryosurgery, only one of six
mice grew tumors (p ¼ 0.025). Four out of five mice treated for MT-
901 tumors by cryoablation grew RENCA tumors, suggesting this was
a tumor-specific immune response.
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NK function was measured in a chromium release assay
against YAC-1 cells. Statistical analysis was performed
using unpaired Student’s t-test. The results are shown in
Figure 6. Mice treated by cryoablation demonstrated
increased NK activity at an E:T ratio of 40:1 (24.5%)
versus mice treated by surgery (16.5%, p < 0.001) or
naı̈ve BALB/c mice (9.6%, p < 0.001).
Discussion
The use of freezing temperatures to treat breast cancer
is not a new concept. Over a century ago, irrigation
devices were designed to bring iced saline solutions in
contact with advanced breast tumors, resulting in the
amelioration of pain and bleeding, and a reduction in
the size of the tumor [20–22] The clinical applicability
of cryosurgery expanded with the introduction of
automated cryosurgical units that pump liquid nitro-
gen through a metal probe. Tanaka treated 49 patients
with advanced or recurrent breast cancer with cryo-
surgery, reporting not only alleviation of pain, control
of hemorrhage, and reduction of tumor bulk, but also
a 5-year survival of 44.4% in this group of ‘incurable’
patients [14]. Suzuki described eight patients with
stage IV breast cancer who had advanced primary
tumors treated by cryosurgery. In addition to pallia-



































































Figure 2. Serum cytokine levels after cryoablation or surgical excision. Blood was drawn 24 h after BALB/c mice underwent either cryoablation
or surgical excision of subcutaneous MT-901 tumors. ELISA was used to measure the presence of Th1 (IL-12, IFN-c) and Th2 (IL-4, IL-10)
cytokines. Groups were compared by unpaired student’s t-test. A significant higher level of both IL-12 (383.6 pg/ml ± 32.8 versus 251.6 ± 16.5,
p ¼ 0.025) and IFN-c (1564 pg/ml ± 49 versus 1244 pg/ml ± 101, p ¼ 0.009) was seen in mice who underwent cryosurgery as compared to mice
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Co-Cultured with MT-901 
Co-Cultured with Line-1
Figure 3. Response in tumor draining lymph nodes after cryoablation or surgical excision. Mice with MT-901 tumors treated by either cryo-
ablation or surgical excision were sacrificed 7 and 12 days after treatment, and TDLN were harvested for CD3/IL-2 activation. 1 · 106 activated
TDLN were co-cultured with irradiated MT-901 or Line-1 tumor cells in the presence of IL-2 (4 IU/ml). The supernatents were collected and
analyzed for IFN-c by ELISA. Mice treated by cryoablation showed a dramatically higher release of IFN-c in response to MT-901 tumor cells
than to Line-1 cells at both time points.
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had resolution of distant disease, including regional
adenopathy, contralateral metastases and pleural
effusion [13]. Clinical observations of sites distant
from the regions treated by cryosurgery have also been
described in other tumor types [23, 24].
Clinical interest in the in situ ablation of breast
cancer has resurfaced with improvements in breast
imaging and ablative technologies. The majority of
these methods are based on thermal destruction of the
tumor, most of which (RFA, laser, microwave, focused
ultrasound) are hyperthermic. Heating above 50 C
causes cell membranes to melt and fuse, and higher
temperatures lead to protein denaturation and irre-
versible cell death [25, 26]. Cryoablation uses freezing
temperatures which exert a much different damaging
effect on tumor cells, including the disruption of met-
abolic pathways, conversion of the lipid layers of the
cell membrane into semisolids, breakdown of the
cytoskeletal microtubular networks, exposure of the
cells to a hyperosmotic environment and the grinding
action of irregular ice formations.
Cryoablation of small breast cancers has recently
been demonstrated to be feasible for tumors < 1 cm in
size, and invasive ductal carcinomas < 1.5 cm [27, 28]
Radiofrequency ablation and laser interstitial therapy
have also been described to be successful for tumors <
1.5 cm size [29, 30]. There are advantages and disad-
vantages to all of these approaches, including potential
side effects, clinical applicability, or anesthesia require-
ments. However, if cryosurgery can induce an anti-tu-
mor immune response capable of preventing recurrence,
it may prove to be superior not only to other ablative
technologies, but to lumpectomy as well.
To elicit the mechanisms behind any cryo-induced
immune response, we utilized a weakly immunogenic
mammary adenocarcinoma cell line, MT-901, in BALB/
c mice. In all experiments, we compared cryosurgery
(freezing the tumor and leaving it in place) to surgical
resection of the tumor. In previous reports, results have
been mixed as to whether cryoablation of breast tumors,
as compared to surgical excision, stimulates an immune
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Figure 4. Response in splenocytes after cryoablation or surgical exci-
sion by IFN-c release assay. Mice with MT-901 tumors treated by
either cryoablation or surgical excision were sacrificed 7 days later, and
spleens were harvested for CD3/IL-2 activation. 1 · 106 activated
splenocytes were co-cultured with irradiated MT-901 or Line-1 tumor.
The supernatents were collected and analyzed for interferon-c (IFNc)
by ELISA. Although there appeared to be a non-specific activation of
lymphocytes, there was no significant difference in the tumor-specific
response between cryoablation and surgery. These results were iden-




Figure 5. Response in splenocytes after cryoablation or surgical exci-
sion by ELISPOT assay. The number of IFN-c producing cells was
measured using ELISPOT assay at varying time points after either
cryoablation or surgical excision. Activated splenocytes (2 · 105 cells/
well) were cultured for 48 h alone or in the presence of irradiated MT-
901 or Line-1 tumor cells in plates coated with anti-mouse IFN-c
antibody. After that time, wells were washed and incubated overnight
with a different clone of biotinylated anti-IFN-c antibody (PharMin-
gen). Reactions were visualized and counted using anti-biotin-AP.
ELISPOT assay demonstrated no difference in the systemic T-cell re-
sponse between cyroablation and surgical excision.





















Figure 6. Natural killer (NK) cell function after cryoablation or sur-
gical excision. Mice with MT-901 tumors treated by either cryoabla-
tion or surgical excision were sacrificed 7 days later, and spleens were
harvested for a cytotoxicity assay against YAC-1, an NK-susceptible
cell line. The % Specific Lysis was calculated using the formula {%
Specific Lysis ¼ 100% · (Lysis ) Average Spontaneous Lysis)/
(Average Total Lysis ) Lysis)}. The p values were determined using t-
test assuming equal variances. Mice treated by cryoablation demon-
strated increased YAC-1 cytotoxicity (24.5% ± 17.3) versus both
mice treated by surgery (16.5% ± 5.9, p < 0.001) or naı̈ve BALB/c
mice (9.6% ± 1.3, p < 0.001). The difference between mice with MT-
901 tumors surgically excised was significantly increased over naı̈ve
mice (p ¼ 0.002).
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studies showed no difference between cryoablation and
surgery [31]. Most studies, however, have demonstrated
a benefit to cryosurgery, although in some of these cases
the response may have been non-specific [32–36]. Our
results not only confirm that cryosurgery, can prevent
re-challenge but also that this response is tumor-specific,
as it did not prevent a secondary non-mammary ade-
nocarcinoma cell line.
More importantly, it is imperative to understand the
mechanisms behind this response if it to be utilized
clinically. The tissue destruction that occurs during in
situ freezing is accompanied by an inflammatory re-
sponse in which many different cytokines may be pro-
duced [37]. In fact, this has been of interest in hepatic
cryoablation as the release of pro-inflammatory cyto-
kines has been associated with distant organ injury after
freezing of large liver tumors (‘cryoshock’) [38, 39]. The
types of cytokines that increase after cryosurgery would
influence the type of immune response generated.
Therefore, we examined both Th1 and Th2 cytokines in
the serum of mice treated by cryoablation or surgical
resection. Levels of IL-12 and IFN-c were significantly
increased 24 h after cryoablation compared to surgery,
while there were no differences in IL-4 and IL-10. These
results suggest that cryosurgery promotes the inflam-
matory cytokines involved in cell-mediated immunity.
We next examined both T-cell function and NK-cell
function after cryosurgery compared to surgery. To look
for the presence of a T-cell response, we utilized an IFN-
c release assay of lymphocytes from the tumor draining
lymph nodes (TDLN) and spleens. In the TDLN of mice
treated with cryoablation, lymphocytes demonstrated a
dramatic increase in IFN-c when cultured in the pres-
ence of irradiated MT-901. This was a tumor-specific
response, as lymphocytes cultured with Line-1 did not
stimulate IFN-c production. This response was not seen
in mice undergoing surgical excision.
This tumor specific response raises the possibility
that cryoablation may be a beneficial adjunct to adop-
tive immunotherapy; the passive administration of cells
with anti-tumor activity to the tumor-bearing host. The
primary obstacle to adoptive immunotherapy has been
generating sufficient numbers of tumor-specific cells for
transfer, as there are few among the peripheral blood
lymphocytes and the harvesting of tumor infiltrating
lymphocytes from breast tumors is technically chal-
lenging. In some breast cancer patients, tumor-reactive
T-lymphocytes expanded from regional lymph nodes
demonstrate tumor-specific responses [40, 41]. Cryoab-
lation of tumor prior to harvest of the regional lymph
nodes may provide a richer source of tumor-specific T-
cells for eventual transfer back to the patient.
Systemically, although there appeared to be an in-
creased non-specific in vivo stimulation of T-cells with
cryosurgery, there was no significant increase in tumor
recognition as measured by cytokine release assay of
the splenocytes. IFN-c ELISPOT assay confirmed no
change in tumor-specific T-cells between mice that
underwent cryoablation or surgical resection at either 2
or 3 weeks after treatment. In contrast to this finding,
systemic NK cell responses increased after cryoabla-
tion. Cryoablation of MT-901 in BALB/c mice also led
to an increase in both serum IL-12 and IFN-c, both of
which have been shown to augment NK cell prolifer-
ation and activation [42]. These results are consistent
with Bayjoo et al. [43]. who demonstrated an increase
in NK cell cytotoxicity after cryosurgery. Although
NK cells are not considered to be tumor-specific, a
subpopulation called NKT cells, which express both
NK cell receptors and a T-cell receptor, demonstrate
antigen specific cytotoxicity [44, 45]. NKT cells are
activated by IL-12 [46], and may be responsible for the
tumor-specific prevention of re-challenge after cryoab-
lation seen in this model.
The majority of the evidence for cryoimmunologic
responses comes from reports of distant disease resolv-
ing after ablation of a primary tumor. Several isolated
studies from the 1980’s attempted to characterize the
immunologic changes in patients undergoing cryoabla-
tion of oral cavity cancers [47, 48] rectal cancer [49, 50]
or breast cancer [13]. Although they demonstrated in-
creases in non-specific markers of immune response,
they were limited by the available immunologic assays.
More recently, Ravindranath et al. [51] demonstrated
that cryoablation of colorectal metastases to the liver led
to the augmentation of serum antibodies against cancer-
associated gangliosides. This rise in anti-tumor anti-
bodies was not seen with RFA or surgical resection. The
authors suggest that cryosurgery is similar to autologous
vaccines because it releases autologous tumor-antigens,
thereby augmenting the immune response to the tumor
itself. The clinical feasibility of autologous tumor vac-
cines for breast cancer patients is extremely limited given
the small amount of tumor available and the difficulty in
establishing breast cancer cell lines. Cryoablation of
breast cancer, even if it needs to be followed by lump-
ectomy for local control, may therefore be an attractive
form of immunotherapy that can help prevent recur-
rence.
Additional information is needed on the mechanisms
by which cryoablation may stimulate tumor immunity in
order to amplify the response. The results of these studies
demonstrate that cryoablation is superior to surgical
excision in terms of stimulating T-cell and NK cell
activity and in preventing tumor growth after re-chal-
lenge. This immunologic response is clearly limited,
however, because a brisk T-cell response was present in
the tumor draining lymph nodes, but not in the spleno-
cytes. As with autologous vaccines, it may be necessary
to augment this immunologic response with an adjuvant.
Several studies have demonstrated that the immune re-
sponse initiated by cryoablation can be amplified by
injecting BCG into the lesion [52, 53]. One could envision
a combination of cryoablation and intralesional cyto-
kines [54] or systemic cytokines to achieve this goal.
Further research on the optimum methods for increasing
the cryoimmunologic response and realizing the clinical
benefit in the treatment of breast cancer is warranted.
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